Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years

(MedPage Today) -- ORLANDO--Patients with hemophilia B continued to experience low annualized bleeding rates and stable endogenous factor IX expression 5 years after a single infusion of etranacogene dezaparvovec (Hemgenix), the final analysis...